DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the strategy of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with DiaMedica Therapeutics, Inc. (DMAC) currently holding a Momentum Style Score of B [2][3] Group 2: Performance Metrics - DMAC shares have increased by 15.47% over the past week, while the Zacks Medical - Biomedical and Genetics industry has decreased by 0.11% during the same period [5] - Over the past quarter, DMAC shares have risen by 86.86%, and by 60.23% in the last year, compared to the S&P 500's increases of 10.17% and 18.61%, respectively [6] - The average 20-day trading volume for DMAC is 444,435 shares, indicating a bullish sign if the stock price rises with above-average volume [7] Group 3: Earnings Outlook - In the past two months, one earnings estimate for DMAC has increased, raising the consensus estimate from -$0.72 to -$0.65 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings outlook [9] Group 4: Conclusion - DMAC is rated as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]